Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Short-term Investments: 2023-2025

Historic Short-term Investments for Immunome (IMNM) over the last 1 years, with Jun 2025 value amounting to $124.2 million.

  • Immunome's Short-term Investments rose 9.89% to $124.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $124.2 million, marking a year-over-year increase of 9.89%. This contributed to the annual value of $74.0 million for FY2024, which is 87.40% up from last year.
  • Latest data reveals that Immunome reported Short-term Investments of $124.2 million as of Q2 2025, which was up 108.01% from $59.7 million recorded in Q1 2025.
  • In the past 5 years, Immunome's Short-term Investments ranged from a high of $124.2 million in Q2 2025 and a low of $39.5 million during Q4 2023.
  • Its 3-year average for Short-term Investments is $76.4 million, with a median of $74.0 million in 2024.
  • Data for Immunome's Short-term Investments shows a peak YoY spiked of 87.40% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Immunome's Short-term Investments stood at $39.5 million in 2023, then surged by 87.40% to $74.0 million in 2024, then grew by 9.89% to $124.2 million in 2025.
  • Its last three reported values are $124.2 million in Q2 2025, $59.7 million for Q1 2025, and $74.0 million during Q4 2024.